Daratumumab, Bortezomib, and Dexamethasone for treatment of patients with relapsed or refractory multiple myeloma and severe renal impairment: results from the phase 2 GMMG-DANTE trial - Leypoldt, Lisa; Gavriatopoulou, Maria; Besemer, Britta; Salwender, Hans; Raab, Marc-Steffen; Nogai, Axel; Khandanpour, Cyrus; Runde, Volker; Jauch, Anna; Zago, Manola; Martus, Peter; Goldschmidt, Hartmut; et al. (Cancers, 2023)
Veröffentlicht: 21. September 2023